CRKL (CRK-like) antibody is a crucial tool in studying the adaptor protein CRKL, encoded by the *CRKL* gene in humans. CRKL belongs to the CRK protein family, characterized by Src homology 2 (SH2) and Src homology 3 (SH3) domains that mediate protein-protein interactions. It plays a pivotal role in intracellular signaling pathways, particularly in regulating cell proliferation, adhesion, migration, and apoptosis. CRKL acts downstream of tyrosine kinases, linking activated receptors (e.g., EGFR, BCR-ABL) to effectors like RAS-MAPK and PI3K/AKT pathways. Dysregulation of CRKL is implicated in cancers (e.g., leukemia, lung, and ovarian cancers), where overexpression or aberrant phosphorylation drives oncogenic signaling.
CRKL antibodies are widely used in research to detect CRKL expression, phosphorylation status, and interactions in cell lysates (via Western blot, IP) or tissue sections (via IHC/IF). They aid in exploring CRKL's role in disease mechanisms, therapeutic responses, and as a potential biomarker. Monoclonal or polyclonal CRKL antibodies are typically raised against specific epitopes (e.g., human CRKL N-terminal or C-terminal regions) and validated for specificity across species (human, mouse, rat). Researchers rely on these antibodies to investigate CRKL's involvement in pathologies, including its interaction with downstream targets like C3G, SOS1. and CAS. Quality validation (e.g., knockout cell controls) ensures antibody reliability for experimental reproducibility.